Digestery
Longevity supplements › NMN and Aging › Studies

Randomized trial · measured lab tests or safety

A 3-week NR trial in 12 older men: less blood inflammation, muscle energy unchanged

Elhassan and colleagues · Cell reports · 2019

Original title: Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

Mixed

NR raised NAD+ related compounds in muscle and lowered blood inflammation markers. Muscle energy-making function did not change.

The study at a glance

Type of study
Randomized trial
Who or what was studied
12 people · Older men
What was tested
NR 1 g a day for 21 days, vs placebo (crossover)
What it measured
Lab tests or markers
Daily amount
1 g a day
How long
3 weeks
Who has a stake
Company stake
One author holds patents licensed by ChromaDex, owns its stock and advises it.
Journal
Cell reports, 2019
Source
PubMed record 31412242. This page is based on the abstract only.

How much this study counts

  • ✓Randomized: people were put into groups by chance, so the groups start out alike.
  • ✓Compared with a placebo, a dummy treatment.
  • –Small: 12 people. Small trials can miss real effects or find chance ones.
  • –Short: 3 weeks. Longer-term effects are unknown.
  • –Measured lab tests or markers, which stand in for aging and age-related decline. A better marker does not always mean better health.
  • –Company stake: One author holds patents licensed by ChromaDex, owns its stock and advises it.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

Each dot is one on-topic paper on this question. Steps near the top answer the question more directly.

↑ Stronger evidence

  1. Trials in people: aging and age-related decline

    0

    Not done yet. This is the step that would answer the question.

  2. Trials in people: other measures

    9

    3 benefit, 2 mixed, 4 no difference

  3. Trials in people: lab tests or safety

    7

    4 benefit, 1 mixed, 2 no difference

    ↑ This study is the ringed dot

  4. Population studies

    0

    None among the papers we read.

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    6

    5 benefit, 1 mixed

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does NMN slow aging?”

Not shown in people so far.

Confidence: very low. Based on 29 on-topic papers.

Read the full answer

Of the other 6 papers on the same step: 4 benefit, 2 no difference. This one found mixed. It differs from most of them.

Other papers on the same step

See all 29 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The two reads agreed on every checked field. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.